News stories about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.8104135196735 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Concert Pharmaceuticals (CNCE) Coverage Initiated at Mizuho (americanbankingnews.com)
- Concert Pharmaceuticals (CNCE) Raised to Buy at ValuEngine (americanbankingnews.com)
- Concert Pharmaceuticals (CNCE) Cut to C at TheStreet (americanbankingnews.com)
- Analysts Expect Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $20,000.00 (americanbankingnews.com)
Shares of NASDAQ CNCE traded down $0.78 during mid-day trading on Friday, hitting $19.01. The company had a trading volume of 314,101 shares, compared to its average volume of 258,427. The stock has a market capitalization of $459.79, a price-to-earnings ratio of 4.66 and a beta of 1.02. Concert Pharmaceuticals has a one year low of $11.88 and a one year high of $30.71.
CNCE has been the topic of several research analyst reports. BidaskClub raised Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. TheStreet raised Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Monday, January 8th. UBS set a $34.00 price target on Concert Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. ValuEngine downgraded Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Zacks Investment Research downgraded Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Concert Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $25.67.
In other news, Director Richard Aldrich sold 30,000 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $19.35, for a total value of $580,500.00. Following the completion of the transaction, the director now owns 286,975 shares in the company, valued at approximately $5,552,966.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 136,236 shares of company stock valued at $2,688,563 in the last 90 days. 10.10% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3338936/concert-pharmaceuticals-cnce-earns-coverage-optimism-score-of-0-10.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.